Oligo sequence for shRNA cloning TurboGFP shRNA upper strand CCGGCGTGATCTTCACCGACAAGATCTCGAGATCTTGTC GGTGAAGATCACGTTTTT TurboGFP shRNA bottom strand AATTAAAAACGTGATCTTCACCGACAAGATCTCGAGATC.

Slides:

Advertisements

Similar presentations

Legends for supplementary figures Fig s1. A: Western blot showing the suppression of SRp20 expression by Dox induction of SRp20 siRNAs in SKOV3 sublines.

Advertisements

(+++) Normal breast ATM (++) IDC ATM Lymph node metastasis negative positive P-value A B X200 C Vector ATM - WT.

Supplementary Figures: Fig. 1, 2, and 3 show H1299 cells overexpressing Set7/9wt or H297A catalytic mutant and U2-OS, U2-OS Set7/9KD, and U2-OS Set7/9.

Figure S1. RNA-seq results for caveolin-1 (Cav1). Upper panel: UCSC genome browser view. Lower panel: quantification o f Cav1 expression based on RNA-seq.

ER  HSP90 DMSO 200  M I3C30  M DIM200  M TRYPTOPHOL Supplemental Figure 1. DIM and Tryptophol fail to induce the downregulation of ER  seen with I3C.

Ratio Frequency Supplemental Figure S1 : A representative histogram showing the distribution of the incorporation ratios in proteins.

Ct log DNA （ pmol) P1P2 Supplementary Fig. S1 Standard curve of the PCR amplification efficiency of transcripts.

Mandal CC et al Supplementary Fig. S1. Increased expression of CSF-1 in human breast cancer cells. (A) The conditioned media from normal human breast epithelial.

1A IP/ Input Figure 1: E47 is present on tRNA genes 1B IgG TFIIB E47 Brf1 WB: Brf1 Input IP A) IP/Input enrichment of E47 at 6 active tRNA genes and one.

Fig.S1. Effects of various inhibitors on LPS-induced TNFα mRNA expression in RAW264.7 cells. The same experimental procedures were performed as described.

Table S1. CD44 expression and clinicopathologic characteristics Cases (n=54) CD44 protein expression P value* Negativ e WeakStrong (n=8)(n=23) Age

Normal skin tissue Supplementary Fig 1A KLF4 has a tumor suppressive function in human skin cancer. Skin cancer tissues were deparaffinized and IHC was.

Supplementary Fig. 1. RT-PCR showed that tumor tissues have elevated Mst1 mRNA levels in most of the HCC patients tested. GAPDH RT-PCR products were shown.

Supplemental Figure 1. The cell death phenotype of fhy3 far1 double mutants. A. The cell death phenotype of fhy3-4 far1-2 mutant plants under LD conditions.

Figure 3. Synergistic effects of the combination of trabectedin and olaparib on poly(ADP-ribosyl)ation and DNA damage in four different breast cancer cell.

Volume 133, Issue 1, Pages (July 2007)

Volume 141, Issue 5, Pages e1 (November 2011)

Ke Xu, Ph.D. Putuo Hospital and Cancer Institute,

Figure S2 apoptosis-PARP -WB

Volume 6, Issue 5, Pages (November 2004)

Volume 145, Issue 2, Pages (August 2013)

Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia by Hironori.

Volume 135, Issue 5, Pages e2 (November 2008)

Volume 135, Issue 3, Pages (September 2008)

Volume 133, Issue 6, Pages (December 2007)

Volume 133, Issue 1, Pages (July 2007)

Volume 141, Issue 5, Pages e1 (November 2011)

EPS15R, TASP1, and PRPF3 Are Novel Disease Candidate Genes Targeted by HNF4α Splice Variants in Hepatocellular Carcinomas Monika Niehof, Jürgen Borlak

Volume 129, Issue 1, Pages (July 2005)

The homeodomain protein Cdx2 regulates lactase gene promoter activity during enterocyte differentiation Rixun Fang, Nilda A. Santiago, Lynne C. Olds,

Volume 135, Issue 3, Pages (September 2008)

by Shrikanth P. Hegde, JingFeng Zhao, Richard A. Ashmun, and Linda H

Toll-Like Receptor 5 Engagement Modulates Tumor Development and Growth in a Mouse Xenograft Model of Human Colon Cancer Sang Hoon Rhee, Eunok Im, Charalabos.

Volume 132, Issue 2, Pages (February 2007)

Volume 133, Issue 6, Pages (December 2007)

I-Cheng Ho, Martin R Hodge, John W Rooney, Laurie H Glimcher Cell

Volume 21, Issue 12, Pages (December 2017)

Volume 145, Issue 2, Pages (August 2013)

MiTF Regulates Cellular Response to Reactive Oxygen Species through Transcriptional Regulation of APE-1/Ref-1 Feng Liu, Yan Fu, Frank L. Meyskens Journal.

Volume 142, Issue 7, Pages e2 (June 2012)

Volume 135, Issue 3, Pages e3 (September 2008)

The M581V Mutation, Associated with a Mild Form of Congenital Insensitivity to Pain with Anhidrosis, Causes Partial Inactivation of the NTRK1 Receptor

Histone deacetylase 1 protein depletion affects general histone acetylation and specific gene expression. Histone deacetylase 1 protein depletion affects.

Rodríguez-Milla Miguel A. , Salinas Julio Molecular Plant

Volume 9, Issue 1, Pages (January 2006)

Volume 25, Issue 6, Pages (March 2007)

Nucleocapsid Phosphorylation and RNA Helicase DDX1 Recruitment Enables Coronavirus Transition from Discontinuous to Continuous Transcription Chia-Hsin.

Volume 6, Issue 3, Pages (September 2004)

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

Volume 36, Issue 2, Pages (October 2009)

Volume 3, Issue 4, Pages (April 2003)

Supplementary Figure 1 A B C SW620 HT29 SW620

HCT-15 HT-29 * Figure S1. Oxaliplatin treatment increases CD44high subpopulations in both HCT-15 and HT-29 cells. Flow.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

Molecular Therapy - Nucleic Acids

Volume 25, Issue 11, Pages e6 (December 2018)

pHSF1Ser230 is upregulated by TNF in colon cancer cells.

Epigenetic regulation of p16INK4a in human gastric cancer.

Volume 2, Issue 4, Pages (October 2012)

A, top, representative Western blot for Ku70 in MCF7 cell extracts following siRNA knockdown of Ku70, compared with siRNA control. A, top, representative.

Effect of G9a on the expression of GSH synthesis enzymes.

Expression of CRC stem cell markers and L1 in CRC cells.

Localization of oxidated thiols in A375 melanoma cells.

Pirh2 represses p73-dependent transactivation.

The Ser124 site of Cdc25A is required for Cdc25A degradation in response to I3C induction. The Ser124 site of Cdc25A is required for Cdc25A degradation.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

SAHA blocks IR-induced increase of RAD51 protein in MM cells.

P53-expressing tumor cells circumvent mitosis, express markers consistent with a G1-like state, and become senescent in response to continuous chemotherapeutic.

Effect of BCAA on the progression of cell cycle, expression of p21CIP1, and induction of apoptosis in HepG2 cells in the presence and absence of visfatin.

H3K36me3 is not essential for LEDGF and MLL target gene occupancy.

Presentation transcript:

Oligo sequence for shRNA cloning TurboGFP shRNA upper strand CCGGCGTGATCTTCACCGACAAGATCTCGAGATCTTGTC GGTGAAGATCACGTTTTT TurboGFP shRNA bottom strand AATTAAAAACGTGATCTTCACCGACAAGATCTCGAGATC TTGTCGGTGAAGATCACG Human PHF2 shRNA-I upper strand GGCCGGGAACGGGAAACTACTCCTTTACTCGAGTAAAG GAGTAGTTTCCCGTTCTTTTTG Human PHF2 shRNA-I bottom strand CTAGCAAAAAGAACGGGAAACTACTCCTTTACTCGAGTA AAGGAGTAGTTTCCCGTTCCC Human PHF2 shRNA-II upper strand CCGGGGCAAGCGCCTGACGTCAAGCCTCGAGGCTTGAC GTCAGGCGCTTGCCTTTTT Human PHF2 shRNA-II bottom strand AATTAAAAAGGCAAGCGCCTGACGTCAAGCCTCGAGGC TTGACGTCAGGCGCTTGCC Primer sequence for Sub-cloning A PHF2(h)_1-186_FORCCGGATCCATGGCGACGGTGCCCGTGTA PHF2(h)_1-186_REVGGGAATTCTTATTGCGGTTGGTGCTGTAGTA PHF2(h)_ _FORCCGGATCCCTGAAGGAGTTTGTGGACTAT PHF2(h)_ _REVGGGAATTCTTATTCTTGTACTTCCACTTGGC PHF2(h)_ _FORCCGGATCCCAAACCAAGAGCAAGTCAGAG PHF2(h)_ _REVGGGAATTCTTAGGCCTGGCCAGCTCCCCACG PHF2(h)_ _FORCCGGATCCGACTCCTGCCTGCAGACCAC PHF2(h)_ _REVGGGAATTCTTAAAGGAGTAGTTTCCCGTT p53(h)_D1-90_FORTGGCCCCTGTCATCTTCTGT p53(h)_D1-90_REVGAATTCTGCGTAATCCGGTA p53(h)_D90-292_FORAAGAAAGGGGAGCCTCACCA p53(h)_D90-293_REVGGAGGGGGCTGGTGCAGGGG p53(h)_D1-292_FORAAGAAAGGGGAGCCTCACCA p53(h)_D1-292_REVGAATTCTGCGTAATCCGGTA Supplemental Table 1 A Restriction sites are underlined

primer sequence for RT-PCR p21(h)_RT01 -ForAGCGATGGAACTTCGACTTTG p21(h)_ RT01-RevCGAAGTCACCCTCCAGTGGT mdm2(h)_RT01-ForCCGGATCTTGATGCTGGTGT mdm2(h)_RT01-RevCTGATCCAACCAATCACCTGAAT Bax(h)_RT01_ForGTCTTTTTCCGAGTGGCAGC Bax(h)_RT01_RevCCAGTTGAAGTTGCCGTCAGA primer sequence for ChIP p21(h)_P1GGCTGGTGGCTATTTTGTCC p21(h)_P2TCCCCTTCCTCCCTGAAAAC mdm2(h)_P1’AAACCATGCATTTTCCCAGC mdm2(h)_P2’CAGGTCTACCCTCCAATCGC p21(h)_NS1 CAGTGTGGCCAAAGGATCTGACGA p21(h)_NS1 TTGGGGCTGCCTATGTAGTGAA mdm2(h)_NS1’ TCTTGACTTTCATGCAAGTCAAACGG mdm2(h)_NS2’ GAAAGGAAAATATAAGAGGACTG Gapdh(h)_Fwd ATCGGGCCAATCTCAGTCCCTTCCC Gapdh(h)_Rev GCCTGGTTCAACTGGGCACGCACCGA Supplemental Table 1 cont. Supplemental table 1. The oligonucleotide sequences used for cloning of shRNA viral vectors, primers for subcloning of plasmid vectors, and primers for RT-qPCR and Chip-PCR are listed.

p53 functionality and p21 vs PHF2 levels in each tumor Supplemental Table 2 Colon cancers with positive p53 function Patient No. PHF2 levelp21 level SexageTP53 mutationp53 activitynormaltumornormaltumor 4F66WT F64WT M56WT M64WT M71A78S (active) M57Q104L (active) F41Q104L (active) M62WT M60Q104L (active) M79WT M77WT M66S106R (active) M74WT M64WT F67WT

p53 functionality and p21 vs PHF2 levels in each tumor Supplemental Table 2 cont. Colon cancers with negative p53 function Patient No. PHF2 levelp21 level SexageTP53 mutationp53 activitynormaltumornormaltumor 2F64R273C (inactive) M75R248Q (inactive) F55R175H (inactive) F58Y234C (inactive) M68insertion after S106n/a M62R342STOPn/a F61V143E (inactive) M56insertion after S106N/A F70P151H (inactive) F62F54I, C141Y (inactive)71.7, F62R248Q (inactive) F57R337P (inactive) M62Y205N (inactive) F65R337P (inactive) Supplemental table 2. The p53 cDNA was sequenced in 30 colorectal cancer tissues. According to functional status of p53, the cancer tissues are divided into two groups, active p53 and mutant p53. PHF2 and p21 levels shown in Figure 6a are listed together.

Case No DiagnosisAGESEXT_stageN_stageM_stageDIFF 1Adenocarcinoma62FpT3pN1.Moderately 2Adenocarcinoma56MpT3pN1.Moderately 3Adenocarcinoma64FpT4bpN2.Moderately 4Adenocarcinoma58FpT3pN0.Moderately 5Adenocarcinoma68MpT3pN1.Moderately 6Adenocarcinoma79MpT3pN0.Poorly 7Adenocarcinoma62MpT3pN1b.Moderately 8Adenocarcinoma61FpT3pN2.Moderately 9Adenocarcinoma64FpT3pN0.Moderately 10Adenocarcinoma57FpT3pN0.Moderately 11Adenocarcinoma60MpT4bpN1.Well 12Adenocarcinoma57MpT2pN0.Moderately 13Adenocarcinoma71MpT3pN1.Moderately 14Adenocarcinoma62MpT3pN1.Well 15Adenocarcinoma62MpT3pN0.Moderately 16Adenocarcinoma41FpT3pN0.Moderately 17Adenocarcinoma64MpT3pN0.Well 18Adenocarcinoma75MpT3pN0.Moderately 19Adenocarcinoma66FpT3pN2.Moderately 20Adenocarcinoma62FpT3pN0.Moderately 21Adenocarcinoma70FpT4bpN0.Moderately 22Adenocarcinoma77MpT3pN1.Moderately 23Adenocarcinoma55FpT3pN1.Moderately 24Adenocarcinoma64MpT3pN0.Moderately 25Adenocarcinoma74MpT3pN0.Well 26Adenocarcinoma67FpT3pN0.Moderately 27Adenocarcinoma62MpT3pN1.Moderately 28Adenocarcinoma66MpT3pN0.Moderately 29Adenocarcinoma65FpT4bpN1.Moderately 30Adenocarcinoma56MpT3pN2.Moderately Supplemental Table 3 Patient Demographics for colon cancer tissue array

Case No. DiagnosisAgeSexT stageN stageDiff 1adenocarcinoma40MpT4apN3a poorly differentiated 2adenocarcinoma43FpT4apN0 poorly differentiated 3adenocarcinoma61FpT3pN3a moderately differentiated 4signet ring cell carcinoma45FpT3pN3a 5adenocarcinoma67MpT3pN1 poorly differentiated 6adenocarcinoma53FpT3pN3a poorly differentiated 7adenocarcinoma67MpT4apN3b moderately differentiated 8adenocarcinoma72MpT3pN3a poorly differentiated 9mucinous adenocarcinoma61MpT1bpN2 10adenocarcinoma65MpT4apN0 poorly differentiated 11adenocarcinoma70MpT4apN2 moderately differentiated 12adenocarcinoma62MpT3pN2 well differentiated 13signet ring cell carcinoma62FpT3pN2 14papillary adenocarcinoma52MpT2pN0 15adenocarcinoma60MpT3pN3a poorly differentiated 16adenocarcinoma66MpT4apN3b poorly differentiated 17signet ring cell carcinoma41MpT3pN3a 18adenocarcinoma60FpT3pN3a poorly differentiated 19adenocarcinoma59MpT4apN3b poorly differentiated 20adenocarcinoma62MpT3pN3b poorly differentiated 21adenocarcinoma49MpT4bpN3b poorly differentiated 22mucinous adenocarcinoma64MpT3pN1 23undifferentiated carcinoma55MpT4apN3b 24adenocarcinoma56FpT3pN2 poorly differentiated 25adenocarcinoma48MpT3pN2 poorly differentiated 26mucinous adenocarcinoma65FpT4apN3a 27adenocarcinoma63MpT3pN2 well differentiated 28adenocarcinoma60MpT3pN0 well differentiated 29signet ring cell carcinoma42MpT3pN1 30mucinous adenocarcinoma55MpT30pN3a Supplemental Table 3 cont. Patient Demographics for stomach cancer tissue array

31adenocarcinoma58MpT3pN3b moderately differentiated 32adenocarcinoma72FpT1bpN2 moderately differentiated 33adenocarcinoma53MpT3pN0 poorly differentiated 34adenocarcinoma46MpT4bpN0 poorly differentiated 35adenocarcinoma64MpT2pN1 moderately differentiated 36adenocarcinoma65MpT2pN1 poorly differentiated 37adenocarcinoma45FpT2pN1 poorly differentiated 38adenocarcinoma58FpT3pN0 well differentiated 39adenocarcinoma68FpT3pN3a poorly differentiated 40adenocarcinoma66MpT4apN3a poorly differentiated 41adenocarcinoma63MpT3pN0 poorly differentiated 42adenocarcinoma52FpT3pN2 moderately differentiated 43adenocarcinoma35FpT1apN0 poorly differentiated 44adenocarcinoma44FpT1bpN0 well differentiated 45adenocarcinoma55MpT1apN0 well differentiated 46signet ring cell carcinoma40MpT1apN0 47adenocarcinoma66MpT1bpN0 moderately differentiated 48adenocarcinoma65FpT1bpN0 moderately differentiated 49adenocarcinoma62FpT1bpN0 poorly differentiated 50adenocarcinoma60FpT1bpN0 moderately differentiated 51adenocarcinoma70FpT1bpN1 moderately differentiated 52adenocarcinoma52MpT1bpN0 well differentiated 53signet ring cell carcinoma40MpT1bpN1 54signet ring cell carcinoma34FpT1apN1 55adenocarcinoma60MpT1bpN0 well differentiated 56adenocarcinoma68MpT1bpN1 well differentiated 57adenocarcinoma52MpT2pN0 well differentiated 58signet ring cell carcinoma62MpT1apN0 59adenocarcinoma60MpT2pN0 well differentiated Supplemental Table 3 cont. Patient Demographics for stomach cancer tissue array Supplemental table 3. Demographic information on patients, stages and differentiation degree in colon and stomach cancer arrays used for Figure 6e-h is listed.

C. PARP C. Casp 3 C. Casp 9 Tubulin C. PARP C. Casp 3 C. Casp 9 Tubulin HepG2 Hep3B DOX PBSOxa5-FU Sh-Con Sh-PHF2-I DOX PBSOxa5-FU Sh-Con Sh-PHF2-I C. PARP C. Casp 3 C. Casp 9 Tubulin DOX PBSOxa5-FU Sh-Con Sh-PHF2-I C. PARP C. Casp 3 C. Casp 9 Tubulin DOX PBSOxa5-FU Sh-Con Sh-PHF2-I KATO IIIMKN-74 C. PARP C. Casp 3 C. Casp 9 Tubulin DOX PBSOxa5-FU Sh-Con Sh-PHF2-I C. PARP C. Casp 3 C. Casp 9 Tubulin DOX PBSOxa5-FU Sh-Con Sh-PHF2-I MDA-MB231 MCF7 Supplemental Fig. 1 Figure S1. Indicated stable cells were treated with PBS, 12.5 mM oxaliplatin, 50 mM 5- FU or 0.5 mM doxorubicin for 16 hours and apoptotic markers were analyzed by Western blotting using indicated antibodies.

Total H3 H3K4-Me2 H3K9-Me2 H3K27-Me2 H3K36-Me2 H3K72-Me2 Sh-Con +-- Sh-PHF2-I -+- Sh-PHF2-II --+ Supplemental Fig. 2 Figure S2. Histone methylation status in PHF2 knock down cell lines was measured. Protein extract from HCT116 stable cells underwent western blotting with methyl-specific antibodies..

Sh-Con Sh-PHF2 OxaPBS Supplemental Fig. 3 Figure S3. Xenograft tumor sizes after PBS or Oxaliplatin (Oxa) treatment.